RNS Number: 6717V PureTech Health PLC 22 September 2026 22 September 2026 PureTech Health plc - Half-Year Report Delivered significant progress across the portfolio, including Seaport's Nasdaq IPO, Celea's financing and Phase 3 trial initiation, and Gallop's positive Phase 1b data, successful
RNS Number: 4709V PureTech Health PLC 21 September 2026 21 September 2026 PureTech Health plc PureTech Announces Successful End-of-Phase 1 Meeting with U.S. Food and Drug Administration (FDA) and Receipt of Fast Track Designation for LYT-200 in Relapsed/Refractory (R/R) High-Risk Myelodysplastic
RNS Number: 1273U PureTech Health PLC 09 September 2026 9 September 2026 PureTech Health plc PureTech Founded Entity Seaport Therapeutics Reports Positive Topline Results from Phase 1 Driving Simulation Trial of GlyphAllo™ in Healthy Volunteers PureTech Health plc (LSE: PRTC) (" PureTech "
RNS Number: 4123T PureTech Health PLC 04 September 2026 4 September 2026 PureTech Health plc Notice of Half-Yearly Results PureTech Health plc (LSE: PRTC) (" PureTech " or the "Company") plans to announce its half-yearly results for the six months ended 30 June 2026 on Tuesday 22 September 2026.
RNS Number: 0041S PureTech Health PLC 25 August 2026 25 August 2026 PureTech Health plc PureTech Founded Entity Celea Therapeutics to Deliver Two Presentations at the Upcoming European Respiratory Society (ERS) Congress Presentations will highlight Celea's differentiated approach to